Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Nov 13;31(17):2337-2344.
doi: 10.1097/QAD.0000000000001621.

Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation

Michael T Yin  1 , Ellen S Chan, Todd T Brown, Pablo Tebas, Grace A McComsey, Kathleen M Melbourne, Andrew Napoli, William R Hardin, Heather J Ribaudo, Edgar T Overton; A5280 Study Team
Affiliations
Randomized Controlled Trial

Racial differences in calculated bioavailable vitamin D with vitamin D/calcium supplementation

Michael T Yin et al. AIDS. .

Abstract

Objectives: Some studies suggest that bioavailable 25-dihydroxyvitamin D [25-(OH)D] is more accurate than total 25-(OH)D as an assessment of vitamin D (VitD) status in black individuals. We hypothesized that increases in bioavailable 25-(OH)D would correlate better with improvement in bone outcomes among black HIV-infected adults.

Design: This is a secondary analysis of AIDS Clinical Trials Group A5280, a randomized, double-blind study of VitD3 and calcium supplementation in HIV-infected participants initiating antiretroviral therapy.

Methods: Effect of VitD/calcium on total and calculated bioavailable 25-(OH)D, parathyroid hormone, bone turnover markers, and bone mineral density in black and nonblack participants were evaluated at 48 weeks. Wilcoxon signed-rank tests and Wilcoxon rank sum tests assessed within and between-race differences.

Results: Of 165 participants enrolled, 129 (40 black and 89 nonblack) had complete data. At baseline, black participants had lower total 25-(OH)D [median (Q1,Q3) 22.6 (15.8, 26.9) vs. 31.1 (23.1, 38.8) ng/ml, P < 0.001] but higher bioavailable 25-(OH)D [2.9 (1.5, 5.2) vs. 2.0 (1.5, 3.0) ng/ml, P = 0.022] than nonblack participants. After 48 weeks of VitD/calcium supplementation, bioavailable 25-(OH)D increased more in black than nonblack participants, but there were no between-race differences change in bone turnover markers or bone mineral density. The associations between increases in 25-(OH)D levels and change in bone outcomes appeared similar for both total and bioavailable 25-(OH)D.

Conclusion: Baseline and change in bioavailable 25-(OH)D were higher among black adults initiating antiretroviral therapy with VitD/calcium; however, associations between 25-(OH)D and bone outcomes appeared similar for total and bioavailable 25-(OH)D. The assessment of total 25-(OH)D may be sufficient for evaluation of VitD status in black HIV-infected individuals.

Trial registration number: NCT01403051.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

Figures

Figure 1
Figure 1
Scatter-plots of parathyroid hormone (PTH) on other parameters at baseline by race with LOESS fits - Lines represent non-parametric smooth curves LOESS fits, with corresponding 95% confidence limits in shaded colors.
Figure 2
Figure 2
Boxplots for percent change in 25-(OH)D, vitamin D binding protein (VDBP), bioavailable 25-(OH)D, and parathyroid hormone (PTH) levels by race and treatment arm * Post-hoc Wilcoxon sign-rank p < 0.05 for within-race-group absolute change from baseline to week 48. # Post-hoc Wilcoxon rank sum p<0.001 for difference in absolute change from baseline to week 48 between the two race groups.
See this image and copyright information in PMC

References

    1. Overton ET, Chan ES, Brown TT, Tebas P, McComsey GA, Melbourne KM, et al. Vitamin D and Calcium Attenuate Bone Loss With Antiretroviral Therapy Initiation: A Randomized Trial. Ann Intern Med. 2015;162:815–824. - PMC - PubMed
    1. Cauley JA, Danielson ME, Boudreau R, Barbour KE, Horwitz MJ, Bauer DC, et al. Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women's Health Initiative (WHI) J Bone Miner Res. 2011;26:2378–2388. - PMC - PubMed
    1. Gutierrez OM, Farwell WR, Kermah D, Taylor EN. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporos Int. 2011;22:1745–1753. - PMC - PubMed
    1. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab. 1986;63:954–959. - PubMed
    1. Powe CE, Evans MK, Wenger J, Zonderman AB, Berg AH, Nalls M, et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med. 2013;369:1991–2000. - PMC - PubMed

Publication types

Associated data